Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals uc - naltrexone hydrochloride - tablets - 50mg milligram - drugs used in alcohol dependence

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb (holdings) limited - colestyramine - powder for oral suspension - 4 grams - bile acid sequestrants

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - stavudine - hiv infections - antivirals for systemic use - hard capsuleszerit is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. the duration of therapy with zerit should be limited to the shortest time possible.powder for oral solutionzerit is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. the duration of therapy with zerit should be limited to the shortest time possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 125.875 mg - injection - excipient ingredients: sucrose; water for injections; monobasic sodium phosphate; poloxamer; nitrogen; dibasic sodium phosphate - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - daclatasvir dihydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - daclatasvir dihydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 125.875 mg - injection - excipient ingredients: dibasic sodium phosphate; nitrogen; water for injections; sucrose; poloxamer; monobasic sodium phosphate - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - apixaban, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose; sodium lauryl sulfate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - eliquis is indicated for the prevention of venous thromboembolic events (vte) in adult patients who have undergone elective total hip or total knee replacement surgery.,eliquis is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.,eliquis is indicated for the treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) in adult patients.,eliquis is indicated for the prevention of recurrent dvt and pe in adult patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - atazanavir sulfate, quantity: 341.69 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; iron oxide red; potable water; gelatin; iron oxide black; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone - reyataz is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see 5.1 pharmacodynamic properties: clinical trials).